Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece

ConclusionsThese data highlight the importance of PROs to facilitate personalized treatment strategies in MS. In line with other teriflunomide studies, AURELIO showed stable QoL, efficacy and safety outcomes, and good treatment satisfaction both in treatment-na ïve and previously treated patients in this Greek cohort of patients with RRMS.

http://link.springer.com/10.1007/s40120-022-00384-2

Source: Neurology and Therapy - July 13, 2022 Category: Neurology Source Type: research